Corrected: BUZZ-Valneva falls as FDA and CDC recommend a pause in use of its chikungunya vaccine for elderly patients

Valneva SE

12/05/2025 08:18

Corrects company name in the headline

   ** Shares in Valneva VLS.PA fall 2% as the U.S. Food and Drug Association (FDA) and Centers for Disease Control and Prevention (CDC) recommend the suspension of its chikungunya vaccine IXCHIQ for elderly patients

** The agencies said, on Friday, in a joint press release, they recommend a pause in the use of IXCHIQ in individuals of 60 years old and older while they investigate postmarketing reports of serious adverse events

** "17 serious adverse events, including two that resulted in death, have been reported in individuals 62 through 89 years of age who received IXCHIQ during postmarketing use globally," they said

** Kempen analysts highlight this recommendation came after the U.S. Advisory Committee on Immunization Practices (ACIP) recommends to include a precaution related to the use of IXCHIQ in persons aged more than 65 years old

** Last week, the European Medicines Agency (EMA)also temporarily suspended the use of the vaccine for individuals aged more than 64 years old, pending investigation

** Shares in Valneva reach their lowest price since April 28

 (Reporting by Mathias de Rozario in Gdansk)

 ((mathias.derozario@thomsonreuters.com;))